Graticule Asia Macro Advisors’s Puma Biotechnology PBYI Stock Holding History

Graticule Asia Macro Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-40,210	Closed	-$3.51M	–	114
2017 Q2	$3.51M	Sell	40,210 -6,200	-13%	-$347K	0.17%	79
2017 Q1	$1.73M	Buy	46,410 +21,410	+86%	+$781K	0.1%	103
2016 Q4	$768K	Buy	25,000 +3,138	+14%	+$136K	0.09%	88
2016 Q3	$1.47M	Buy	+21,862	New	+$1.11M	0.1%	73
2016 Q1	–	Sell	-26,700	Closed	-$2.09M	–	157
2015 Q4	$2.09M	Buy	26,700 +6,700	+34%	+$526K	0.34%	49
2015 Q3	$1.51M	Buy	+20,000	New	+$1.89M	0.18%	62

Other funds holding PBYI

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Graticule Asia Macro Advisors's PBYI Position: Q3 2017 in Review

Graticule Asia Macro Advisors sold out of Puma Biotechnology (PBYI) in Q3 2017, closing a stake of 40,210 shares — an estimated $3.51M sold.

Graticule Asia Macro Advisors first reported a position in PBYI in Q3 2015 and held it in 6 quarters. The position peaked at $3.51M in Q2 2017. 171 funds tracked by Wall St. Rank hold PBYI as of Q3 2017.

Graticule Asia Macro Advisors reported no remaining Puma Biotechnology position as of Q3 2017 after selling out during the quarter.
Graticule Asia Macro Advisors sold 40,210 Puma Biotechnology shares in Q3 2017, an estimated $3.51M.
Graticule Asia Macro Advisors first reported a position in Puma Biotechnology in Q3 2015 and held it in 6 quarters.
Graticule Asia Macro Advisors's Puma Biotechnology position peaked at $3.51M in Q2 2017.
171 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.